Back to Search
Start Over
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
- Source :
- Cancer Communications; Sep2021, Vol. 41 Issue 9, p889-903, 15p
- Publication Year :
- 2021
Details
- Language :
- English
- ISSN :
- 25233548
- Volume :
- 41
- Issue :
- 9
- Database :
- Complementary Index
- Journal :
- Cancer Communications
- Publication Type :
- Academic Journal
- Accession number :
- 152469485
- Full Text :
- https://doi.org/10.1002/cac2.12179